for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

NuVasive, Inc.

NUVA.OQ

Latest Trade

64.92USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

28.55

 - 

81.91

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

NuVasive Announces Proposed Offering Of $400 Mln Of Convertible Senior Notes Due 2023

May 26 (Reuters) - NuVasive Inc <NUVA.O>::NUVASIVE, INC. ANNOUNCES PROPOSED OFFERING OF $400 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2023.

Nuvasive Implements Compensation Reductions For Board Of Directors

April 14 (Reuters) - NuVasive Inc <NUVA.O>::SEES Q1 2020 REVENUE $259 MILLION TO $261 MILLION.IMPLEMENTING COMPENSATION REDUCTIONS FOR ITS BOARD OF DIRECTORS AND EXECUTIVE OFFICERS.CONTROLLING DISCRETIONARY SPEND ACROSS ORGANIZATION.ADJUSTING MANUFACTURING CAPACITY BASED ON CERTAIN GOVERNMENT DIRECTIVES AND DEMAND.WITHDRAWAL OF 2020 FINANCIAL GUIDANCE.DECLINE IN ELECTIVE PROCEDURE VOLUMES TO CONTINUE TO HAVE A SIGNIFICANT NEGATIVE IMPACT IN Q2.VISIBILITY FOR SPINE SURGERY VOLUMES FOR REMAINDER OF YEAR IS LIMITED.NOT ABLE TO PREDICT WHEN OR HOW QUICKLY ELECTIVE SURGERY VOLUMES WILL RECOVER..IN NEAR-TERM, EXPECT TO CONTINUE SEEING LOWER ELECTIVE PROCEDURE VOLUMES.

NuVasive Inc Announces Proposed Offering Of $450 Million Of Convertible Senior Notes Due 2025

Feb 26 (Reuters) - NuVasive Inc <NUVA.O>::NUVASIVE, INC. ANNOUNCES PROPOSED OFFERING OF $450 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2025.

Nuvasive Says Q4 Revenue Rose 7.6 Percent To $310.4 Million

Feb 20 (Reuters) - NuVasive Inc <NUVA.O>::NUVASIVE ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $0.73.Q4 GAAP EARNINGS PER SHARE $0.55.Q4 REVENUE ROSE 7.6 PERCENT TO $310.4 MILLION.SEES FY 2020 NON-GAAP EARNINGS PER SHARE $2.55 TO $2.65.SEES FY 2020 GAAP EARNINGS PER SHARE $1.15 TO $1.25.SEES FY 2020 REVENUE UP 4 TO 6 PERCENT.Q4 EARNINGS PER SHARE VIEW $0.64 -- REFINITIV IBES DATA.Q4 REVENUE VIEW $304.8 MILLION -- REFINITIV IBES DATA.FY2020 EARNINGS PER SHARE VIEW $2.60 -- REFINITIV IBES DATA.FY2020 REVENUE VIEW $1.23 BILLION -- REFINITIV IBES DATA."IN 2020, OUR PRIMARY GROWTH DRIVERS INCLUDE CONTINUING TO LEAD IN LATERAL SPINE SURGERY".

Nuvasive Announces Preliminary Unaudited Fourth Quarter And Full Year 2019 Revenue Results

Jan 13 (Reuters) - NuVasive Inc <NUVA.O>::NUVASIVE ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2019 REVENUE RESULTS.NUVASIVE - Q4 2019 PRELIMINARY REVENUE OF ABOUT $310 MILLION.

Nuvasive Appoints Matthew Harbaugh As Chief Financial Officer

Jan 2 (Reuters) - NuVasive Inc <NUVA.O>::NUVASIVE APPOINTS MATTHEW K. HARBAUGH AS CHIEF FINANCIAL OFFICER.NUVASIVE APPOINTS MATTHEW K. HARBAUGH AS CHIEF FINANCIAL OFFICER.NUVASIVE INC - HARBAUGH SUCCEEDS RAJESH ASARPOTA, WHO WILL TRANSITION FROM COMPANY.NUVASIVE INC - NUVASIVE REAFFIRMS ITS ANNUAL FINANCIAL GUIDANCE FOR FULL-YEAR 2019.NUVASIVE INC - ASARPOTA HAS AGREED TO REMAIN WITH COMPANY IN AN ADVISORY ROLE UNTIL MAY 2020 TO ASSIST IN TRANSITION OF DUTIES.NUVASIVE - MOST RECENTLY, HARBAUGH SERVED AS PRESIDENT OF SPECIALTY GENERICS BUSINESS AT MALLINCKRODT PLC.NUVASIVE INC - ASARPOTA TO PROVIDE ONGOING CONSULTING SERVICES UNTIL SEPTEMBER 2020.

Nuvasive Inc Receives FDA Clearance For Expanded Multi-Level Use Of Coroent Small Interlock System For Cervical Spine

Nov 21 (Reuters) - NuVasive Inc <NUVA.O>::NUVASIVE INC - RECEIVES FDA CLEARANCE FOR EXPANDED MULTI-LEVEL USE OF COROENT SMALL INTERLOCK SYSTEM FOR CERVICAL SPINE.

Nuvasive Announces Third Quarter 2019 Financial Results

Oct 30 (Reuters) - NuVasive Inc <NUVA.O>::NUVASIVE ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $0.59.Q3 GAAP EARNINGS PER SHARE $0.21.Q3 REVENUE ROSE 7.2 PERCENT TO $290.8 MILLION.COMPANY RAISES FULL-YEAR 2019 FINANCIAL GUIDANCE..UPDATES FULL-YEAR 2019 REVENUE TO APPROXIMATELY $1.16 BILLION.SEES FY NON-GAAP DILUTED EARNINGS PER SHARE IN A RANGE OF $2.35 TO $2.40.FY REVENUE GROWTH FORECAST ON A CONSTANT CURRENCY BASIS IS IN RANGE OF 5.6% TO 6.3%.FY2019 EARNINGS PER SHARE VIEW $2.32, REVENUE VIEW $1.16 BILLION -- REFINITIV IBES DATA.

Alphatec Announces Favorable Judgment In Nuvasive V. Miles Lawsuit

Aug 27 (Reuters) - Alphatec Holdings Inc <ATEC.O>::ALPHATEC ANNOUNCES FAVORABLE JUDGMENT IN NUVASIVE V. MILES LAWSUIT.ALPHATEC HOLDINGS INC - COURT ENTERED SUMMARY JUDGMENT IN FAVOR OF ITS CHAIRMAN AND CHIEF EXECUTIVE OFFICER, PAT MILES.ALPHATEC HOLDINGS - COURT TERMINATED ALL NON-COMPETITION AND EMPLOYEE NON-SOLICITATION CLAIMS BROUGHT AGAINST MILES AND CO BY NUVASIVE.

Nuvasive Q2 GAAP Earnings Per Share $0.29

July 30 (Reuters) - NuVasive Inc <NUVA.O>::NUVASIVE ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $0.63.Q2 GAAP EARNINGS PER SHARE $0.29.Q2 REVENUE ROSE 3.7 PERCENT TO $292.1 MILLION.SEES FY 2019 REVENUE $1.14 BILLION TO $1.16 BILLION.SEES 2019 NON-GAAP DILUTED EARNINGS PER SHARE IN A RANGE OF $2.25 TO $2.35.FY2019 EARNINGS PER SHARE VIEW $2.28, REVENUE VIEW $1.15 BILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE VIEW $0.56, REVENUE VIEW $290.6 MILLION -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up